BACKGROUND/AIMS: BRCA mutation carriers have a high lifetime risk of developing breast and ovarian malignancies. As genetic testing becomes widely available, preventative measures are a choice. We evaluated the characteristics of BRCA mutation carriers who chose prophylactic surgery (PS) compared to those who opted for surveillance. METHODS: A retrospective chart review of patients with a mutation in the BRCA1 or BRCA2 genes was performed. RESULTS: Ninety women were included, of whom 46 (51%) underwent PS. They were more likely to be a BRCA2 mutation carrier, parous, married, employed, and had a prior history of breast cancer. PS included 39 bilateral salpingo-oophorectomies and 13 mastectomies. Pathology was typically benign; however, 15% showed ductal carcinoma in situ of the breast, 8% reported infiltrating ductal carcinoma of the breast, 3% was adenocarcinoma of the fallopian tube, and 3% was adenocarcinoma of the ovary. CONCLUSION: It is notable that BRCA1 mutation carriers were less inclined to elect for PS. Evaluating the reasons for pursuing PS among women with a BRCA mutation is necessary and will require a larger data set. Long-term follow-up is required to describe the potential side effects of PS on quality of life. Copyright (c) 2010 S. Karger AG, Basel.
BACKGROUND/AIMS: BRCA mutation carriers have a high lifetime risk of developing breast and ovarian malignancies. As genetic testing becomes widely available, preventative measures are a choice. We evaluated the characteristics of BRCA mutation carriers who chose prophylactic surgery (PS) compared to those who opted for surveillance. METHODS: A retrospective chart review of patients with a mutation in the BRCA1 or BRCA2 genes was performed. RESULTS: Ninety women were included, of whom 46 (51%) underwent PS. They were more likely to be a BRCA2 mutation carrier, parous, married, employed, and had a prior history of breast cancer. PS included 39 bilateral salpingo-oophorectomies and 13 mastectomies. Pathology was typically benign; however, 15% showed ductal carcinoma in situ of the breast, 8% reported infiltrating ductal carcinoma of the breast, 3% was adenocarcinoma of the fallopian tube, and 3% was adenocarcinoma of the ovary. CONCLUSION: It is notable that BRCA1 mutation carriers were less inclined to elect for PS. Evaluating the reasons for pursuing PS among women with a BRCA mutation is necessary and will require a larger data set. Long-term follow-up is required to describe the potential side effects of PS on quality of life. Copyright (c) 2010 S. Karger AG, Basel.
Authors: T Pal; J-H Lee; A Besharat; Z Thompson; A N A Monteiro; C Phelan; J M Lancaster; K Metcalfe; T A Sellers; S Vadaparampil; S A Narod Journal: Clin Genet Date: 2013-03-21 Impact factor: 4.438
Authors: Nisreen Elsayegh; Henry M Kuerer; Heather Lin; Angelica M Gutierrez Barrera; Michelle Jackson; Kimberly I Muse; Jennifer K Litton; Constance Albarracin; Aimaz Afrough; Gabriel N Hortobagyi; Banu K Arun Journal: Ann Surg Oncol Date: 2014-05-06 Impact factor: 5.344
Authors: Nisreen Elsayegh; Jessica Profato; Angelica M Gutierrez Barrera; Heather Lin; Henry M Kuerer; Can Ardic; Jennifer K Litton; Debasish Tripathy; Banu K Arun Journal: J Cancer Date: 2015-05-23 Impact factor: 4.207
Authors: Nisreen Elsayegh; Rachel D Webster; Angelica M Gutierrez Barrera; Heather Lin; Henry M Kuerer; Jennifer K Litton; Isabelle Bedrosian; Banu K Arun Journal: Cancer Med Date: 2018-05-07 Impact factor: 4.452
Authors: Julia Hackett; Rachael Thorneloe; Lucy Side; Michael Wolf; Rob Horne; Jack Cuzick; Samuel G Smith Journal: Breast Cancer Res Treat Date: 2018-04-24 Impact factor: 4.872